Clinical and laboratory responses to XXXX in the treatment of hypercholesterolaemia.

@entity1 @entity1671 @entity70960 @entity412 @entity4310 @entity165
Twenty-five hypercholesterolaemic @entity1 from three centres in the UK were investigated in an open study of the efficacy and side effects of @entity70960 . Five @entity1 dropped out of the study at an early stage and had insufficient data for analysis. There were 13 males and 7 females (mean age 49.2 years, range 18-69). Fourteen @entity1 had heterozygous @entity4310 , and six polygenic hypercholesterolaemia. @entity70960 was started at a dose of 750 mg/day and this was increased at weekly intervals over 4 weeks to the maximum tolerated dosage up to 3 g/day. This was then maintained for a further 8 weeks. There were statistically significant decreases in total plasma @entity165 , total @entity412 , LDL @entity165 and VLDL @entity412 ; HDL @entity165 remained unchanged after 12 weeks of treatment (Wilcoxon matched pairs, signed ranks test). The 14 @entity1 with @entity4310 showed a 13.9% fall in total @entity165 and a 19.8% fall in LDL @entity165 . All @entity1 reported @entity1671 and some had gastrointestinal symptoms but 19 would have been prepared to continue with the therapy at doses up to 3 g/day. Thus @entity70960 has been found to be beneficial in the treatment of both @entity4310 .
